Endovia Health Sciences, Inc. EDVA
to manage brands across viable growth segments within the consumer beverage industry. As a result of our lack of capital, we did not generate
revenue from February 2025 until March 2026 when we delivered tequila as described below. Our beverage operations have historically not
been profitable. Because of our lack of capital to generate revenue, our management reviewed strategic alternatives inside and outside
of the beverage industry. As a result, on March 4, 2026 the Company entered into a non-binding letter of intent setting forth the principal
Last close
0.16
2026-10-23
Market cap
$1.0M
2026-06-30 share count
52-week range
0.13 - 0.46
Valuation FY2025 figures against the last close
P/S14.0x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-11.97
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $73.1K | $801.3K | $18.9M | $18.1M | $11.3M | $2.3M | $20.4K | $1.3M | $895.3K | $1.0M |
| Cost of revenue | — | $3.8M | $13.3M | $12.2M | $7.4M | $1.9M | $245.5K | $605.3K | $440.4K | $484.9K |
| Gross profit | $16.9K | -$119.8K | $5.6M | $5.9M | $3.9M | $363.6K | -$225.1K | $703.9K | $454.9K | $527.4K |
| SG&A | — | — | — | — | — | — | $204.1K | $194.3K | $162.5K | $136.1K |
| Total operating expenses | $14.2M | $9.8M | $20.9M | $27.3M | $33.0M | $18.0M | $4.3M | $637.2K | $612.1K | $577.4K |
| Operating income | -$14.2M | -$9.9M | -$15.3M | -$21.4M | -$29.1M | -$17.7M | -$4.5M | $66.7K | -$157.2K | -$50.0K |
| Interest expense | $2.5M | $3.7M | $1.9M | $251.5K | $442.8K | $2.0M | $665.2K | $5.7K | $4.5K | $4.7K |
| Pre-tax income | -$25.2M | -$23.8M | -$21.0M | -$21.7M | -$29.1M | $28.7M | -$5.1M | $68.2K | -$147.5K | -$48.8K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$25.2M | -$23.8M | -$21.0M | -$21.7M | -$29.1M | $28.7M | -$5.1M | $68.2K | -$147.5K | -$48.8K |
| EPS, basic | -11.97 | -17.68 | — | — | -1.02 | -1.06 | -0.04 | 0.01 | — | — |
| EPS, diluted | -11.97 | -17.68 | — | — | -1.02 | -1.06 | -0.13 | 0.01 | -0.01 | 0.00 |
| Shares, diluted (wtd. avg.) | 2.2M | 1.3M | 1.1M | 37.4M | 28.9M | 18.5M | 11.9M | 11.4M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $281.4K | $13.8K | $167.2K | $4.4M | $4.2M | $380.0K | $42.6K | $938.0K | — | — |
| Receivables | $15.7K | $192.0K | $890.6K | $1.8M | $1.1M | $484.9K | $11.4K | $301.0K | $151.3K | $206.3K |
| Inventory | $33.5K | $319.1K | $2.3M | $3.7M | $1.9M | $798.3K | $304.0K | $41.7K | — | — |
| Total current assets | $632.0K | $1.9M | $4.0M | $10.7M | $8.3M | $2.2M | $370.7K | $349.7K | $194.4K | $293.1K |
| Property, plant and equipment | $12.9K | $22.2K | $349.8K | $489.6K | $569.8K | $681.4K | $37.7K | $58.6K | $46.6K | $62.2K |
| Goodwill | — | — | $256.8K | $256.8K | $256.8K | $5.7M | — | — | — | — |
| Other intangibles | — | — | $4.5M | $4.9M | — | — | — | — | — | — |
| Total assets | $965.7K | $2.8M | $9.9M | $17.3M | $16.4M | $9.2M | $605.3K | $408.3K | $241.0K | $355.3K |
| Accounts payable | $4.8M | $3.6M | $4.4M | $3.4M | $1.9M | $1.5M | $703.9K | $331.0K | $226.2K | $209.1K |
| Short-term debt | — | — | — | — | — | — | $3.2K | $8.2K | $11.3K | $10.9K |
| Total current liabilities | $16.3M | $19.4M | $14.8M | $5.0M | $6.5M | $5.4M | $10.3M | $405.5K | $299.9K | $290.4K |
| Long-term debt | $3.4K | $2.0M | $457.7K | $2.5M | $0 | $1.2M | $2.1K | $5.5K | $14.0K | $25.3K |
| Total liabilities | $16.3M | $21.4M | $15.5M | $8.0M | $7.5M | $9.3M | $10.4M | $411.0K | $313.9K | $315.7K |
| Retained earnings | -$181.9M | -$155.8M | -$133.3M | -$112.3M | -$90.6M | -$61.6M | -$31.8M | -$248.2K | -$316.4K | -$168.8K |
| Total equity | -$15.3M | -$18.6M | -$5.6M | $9.3M | $8.9M | -$9.4M | -$9.8M | -$7.8M | -$72.9K | $39.7K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.8M | -$7.3M | -$10.2M | -$14.0M | -$14.7M | -$21.3M | -$2.7M | $62.4K | -$17.6K | $32.1K |
| Depreciation and amortisation | $148.1K | $148.2K | $153.9K | $182.9K | $156.8K | $55.6K | $19.8K | $62.8K | $71.9K | $55.8K |
| Stock-based compensation | $8.6M | $2.4M | $1.2M | $7.4M | $4.0M | $2.3M | $1.6M | $0 | — | — |
| Capital expenditure | — | $3.2K | $14.1K | $102.7K | $0 | $91.1K | $12.6K | $75.6K | $58.3K | $58.4K |
| Investing cash flow | — | -$3.2K | -$14.1K | -$102.7K | $0 | -$768.6K | -$12.6K | -$67.6K | -$42.2K | -$52.1K |
| Financing cash flow | $5.1M | $7.5M | $6.1M | $14.4M | $19.0M | $22.5M | $1.8M | -$5.8K | $16.1K | $74.3K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001731122-26-000640.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $895.3K | $1.3M | $20.4K | $2.3M | $11.3M | $18.1M | $18.9M | $801.3K | $73.1K |
| Gross profit | $527.4K | $454.9K | $703.9K | -$225.1K | $363.6K | $3.9M | $5.9M | $5.6M | -$119.8K | $16.9K |
| Net income | -$48.8K | -$147.5K | $68.2K | -$5.1M | $28.7M | -$29.1M | -$21.7M | -$21.0M | -$23.8M | -$25.2M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Item 7.01
- Material agreement signed Item 1.01
- Material agreement signed Item 1.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2080
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| KO | COCA COLA CO | $398.88B | 30.5x | 1.9% |
| PEP | PEPSICO INC | $185.31B | 22.6x | 2.3% |
| KDP | Keurig Dr Pepper Inc. | $47.19B | 22.7x | 8.2% |
| BF-B | BROWN FORMAN CORP | $13.49B | 19.2x | -1.2% |
| PRMB | Primo Brands Corp | $7.13B | 123.1x | 29.3% |
| COCO | Vita Coco Company, Inc. | $3.24B | 47.5x | 18.2% |
| BRCC | BRC Inc. | $1.33B | — | 1.7% |
| WEST | Westrock Coffee Co | $964.1M | — | 39.8% |